RecruitingPhase 2NCT07267949
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
Clinical Randomised Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
Sponsor
Acesion Pharma
Enrollment
200 participants
Start Date
Oct 22, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new drug called AP31969 to see if it can help control the heart's rhythm in people with atrial fibrillation (AF) — an irregular heartbeat where the heart beats too fast or erratically. The study uses an implanted heart monitor (loop recorder) to track AF over time.
**You may be eligible if...**
- You are 18 or older
- You have been diagnosed with paroxysmal or persistent atrial fibrillation (confirmed by ECG)
- You have had at least one AF episode in the past 4 months, and your AF burden is between 1% and 90% on monitoring
- You agree to have a small loop recorder device implanted under the skin to track your heart rhythm
- You agree to avoid other rhythm control treatments (such as ablation or other antiarrhythmic drugs) for the duration of the trial
**You may NOT be eligible if...**
- You have had a heart attack, stroke, or heart procedure in the past 4 weeks
- You have heart failure of class III or IV severity, or your heart pumps at less than 40% efficiency
- You have significant heart valve disease
- You already have a pacemaker or loop recorder
- You have kidney disease (eGFR below 60)
- You have a prolonged QT interval on ECG
- You have taken certain antiarrhythmic drugs recently
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAP31969
Tablets, Oral, Twice daily.
DRUGPlacebo
Tablets, oral, Twice daily.
Locations(44)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07267949
Related Trials
Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients With Atrial Fibrillation Using a Decentralized Platform
NCT066184171 location
Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)
NCT070024503 locations
Prediction of Atrial Fibrillation Using Polygenic Risk Score
NCT076415825 locations
Cardiac Arrhythmia Telemetry; Conventional vs HeartWatch
NCT061648081 location
Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation
NCT074413821 location